pyridine/脳卒中

The present invention relates to novel crystalline forms of 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo-[4,3-a ]pyridine to pharmaceutical compositions containing such crystal forms and to methods of treatment.

The present invention relates to novel cycloalkyl-[4-(trifluorophenyl)-oxazol-5-yl]-triazolo-pyridines, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the present invention are potent inhibitors of MAP kinases,

CROSS REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Application No. 60/407,489, filed on Aug. 30, 2002. The present invention relates to novel cycloalkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines, to intermediates for their preparation, to

The present invention relates to novel alkyl-[4-(trifluorophenyl)-oxazol-5-yl]-triazolo-pyridines, to intermediates and methods for their preparation, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the present invention are potent inhibitors of MAP

BACKGROUND OF THE INVENTION This invention relates to pyridine derivatives and in particular to certain 2-(1-imidazolymethyl)pyridine derivatives substituted in the pyridine ring. Such compounds are able to selectively inhibit the action of the thromboxane synthetase enzyme without significantly

The present invention relates to disubstituted pyridine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of cell proliferative diseases, inflammatory and immunological

The present invention relates to novel triazolo-pyridines, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the present invention are potent inhibitors of MAP kinases, preferably p38 kinase. They are useful in the

The present invention relates to novel triazolo-pyridines, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the present invention are potent inhibitors of MAP kinases, preferably p38 kinase. They are useful in the

This invention relates to pyridine derivatives, to processes for their preparation and to pharmaceutical compositions containing them. Up to now, of the compounds having a pyridine skeleton, it has been reported that 2-isopropyl-3-nicotinylindole(L-8027) possesses an inhibitory activity on

This invention relates to pyridine derivatives, to processes for their preparation and to pharmaceutical compositions containing them. Up to now, of the compounds having a pyridine skeleton, it has been reported that 2-isopropyl-3-nicotinylindole(L-8027) possesses an inhibitory activity on

BACKGROUND OF THE INVENTION The present invention relates to novel triazolo-pyridines, to methods of preparation, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the present invention are potent inhibitors of MAP

This invention relates to pyridine derivatives, to processes for their preparation and to pharmaceutical compositions containing them. Up to now, of the compounds having a pyridine skeleton, it has been reported that 2-isopropyl-3-nicotinylindole(L-8027) possesses an inhibitory activity on

FIELD OF THE INVENTION The present invention relates to certain imidazo[1,2-.alpha.]pyridine derivatives of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT.sub.2A serotonin receptor. Compounds of Formula (Ia) and pharmaceutical compositions thereof are

FIELD OF THE INVENTION The present invention relates to certain imidazo[1,2-a]pyridine derivatives of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT.sub.2A serotonin receptor. Compounds of Formula (Ia) and pharmaceutical compositions thereof are directed

BACKGROUND OF THE INVENTION This invention relates to compounds that inhibit the activity of protein kinases. Protein kinases are enzymes that catalyze the transfer of a phosphate group from ATP to an amino acid residue, such as tyrosine, serine, threonine, or histidine on a protein. Regulation of